• Eli Lilly has announced plans to invest more than US$3.50 billion in a new injectable-medicine manufacturing facility in Pennsylvania’s Lehigh Valley, dedicated to next-generation weight-loss therapies such as the investigational retatrutide.
• This plant, Lilly’s fourth new U.S. site since 2025, highlights how the group is pairing AI-enabled manufacturing with a large domestic expansion program exceeding US$50.00 billion in capital commitments to support its obesity portfolio.
• With this large-scale U.S. manufacturing build-out aimed at future weight-loss drugs, we’ll examine how it reshapes Eli Lilly’s investment narrative.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Eli Lilly's Investment Narrative?

To own Eli Lilly today, you have to believe its GLP‑1 franchise can keep driving earnings while the company steadily reduces its dependence on a few blockbuster injectables. The new US$3.50 billion Lehigh Valley plant fits that story as a long‑dated, capital‑intensive bet on sustained obesity demand rather than a near‑term catalyst; with operations not expected until 2031, it does little to change the next couple of years, which still hinge on tirzepatide execution, the orforglipron pill decision delay and competitive pressure from Novo Nordisk’s oral Wegovy. Where it does move the needle is on the risk side: Lilly is leaning harder into obesity, adding fixed costs and balance sheet demands to a business that already carries a high valuation, high debt levels and meaningful single‑therapy concentration.

However, investors should also recognize how much of Lilly’s value now rests on a narrow set of obesity assumptions. Despite retreating, Eli Lilly's shares might still be trading 21% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Thirty seven members of the Simply Wall St Community currently place Lilly’s fair value between about US$770 and just under US$1,430, with several clustering above US$1,200. That spread sits against a business where short term share performance is still closely tied to GLP‑1 outcomes and regulatory milestones, even as long term commitments like the new Pennsylvania facility raise the stakes on execution. You can use these very different viewpoints to stress test your own expectations for how Lilly handles those risks and opportunities.

Explore 37 other fair value estimates on Eli Lilly - why the stock might be worth as much as 38% more than the current price!

Build Your Own Eli Lilly Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.